In Vivo's editors, along with experts from the Informa Pharma Intelligence team, selected five top picks for the most significant M&A, alliance and financing deals of 2022. The votes have been counted and it is time to crown the winners.
Takeda Pharmaceutical Co. Ltd. agreed to pay privately-held Nimbus Therapeutics, Inc. $4bn upfront for a Phase IIb asset, with plans to take it into Phase III in psoriasis...